Actinium Pharmaceuticals (NYSE:ATNM) Receives Buy Rating from HC Wainwright

Posted by Donald Scott on Apr 1st, 2025

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 148.45% from the stock’s current price.

Actinium Pharmaceuticals Stock Down 11.0 %

Shares of ATNM opened at $1.61 on Tuesday. The company has a 50 day moving average of $1.26 and a two-hundred day moving average of $1.44. Actinium Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $10.24. The company has a market cap of $50.23 million, a price-to-earnings ratio of -1.16 and a beta of 0.10.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new stake in Actinium Pharmaceuticals in the third quarter worth about $112,000. XTX Topco Ltd purchased a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at approximately $268,000. Barclays PLC boosted its stake in Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares in the last quarter. Geode Capital Management LLC grew its position in Actinium Pharmaceuticals by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after purchasing an additional 19,843 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in Actinium Pharmaceuticals during the 4th quarter valued at approximately $32,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).